Blockchain Registration Transaction Record

Cybin CMO to Speak at 2025 Milken Institute Health Summit

Cybin Inc. announces CMO participation at 2025 Milken Institute Health Summit. Learn about their Phase 3 psychedelic treatments for depression and anxiety disorders.

This development matters because mental health disorders affect hundreds of millions globally, with current treatments often providing inadequate relief or causing significant side effects. Cybin's innovative psychedelic-based therapies represent a potential paradigm shift in psychiatric care, offering hope for more effective and durable treatments for conditions like major depressive disorder and generalized anxiety disorder. The company's participation at the prestigious Milken Institute summit signals growing mainstream acceptance of psychedelic medicine and could accelerate regulatory approval pathways. For patients who have found limited success with traditional antidepressants and therapies, these breakthrough treatments could provide life-changing relief. Additionally, as mental healthcare costs continue to burden healthcare systems worldwide, more effective treatments could reduce long-term healthcare expenditures while improving quality of life for millions suffering from treatment-resistant mental health conditions.